



April 16, 2025

First Choice Next Formulary GLP-1 Medications

First Choice Next formulary GLP-1 medications (Mounjaro, Ozempic, Rybelsus, Trulicity) are updating from requiring a step therapy with Metformin to a prior authorization requiring the following:

Initial authorization:

- Diagnosis of Type 2 Diabetes Mellitus
- Requested dose is appropriate per labeling
- Age restriction is appropriate per package insert
- Documentation of laboratory results that meet one of the following values:

o A1C >= 6.5

o Fasting plasma glucose (FPG) >= 126mg/dL

- o 2-hour plasma glucose (PG) >= 200 mg/dL during OGTT (oral glucose tolerance test)
- o Random Plasma Glucose >= 200 mg/dL

Reauthorization:

- Documentation of positive clinical response to therapy (e.g., A1C lab results)
- Requested dose is appropriate per labeling
- Age restriction is appropriate per package insert

The above prior auth criteria is effective 4/15/2025 for new starts and 7/1/2025 for our current members on a GLP-1 medication.

If you have any questions, please reach out to First Choice Next Pharmacy Services at 1-833-779-7229.

AmeriHealth Caritas Next and First Choice Next are individual and family health plans offered both on and off the Health Insurance Marketplace® by certain companies within the AmeriHealth Caritas Family of Companies. AmeriHealth Caritas Next is offered by AmeriHealth Caritas VIP Next, Inc. in Delaware; AmeriHealth Caritas Florida, Inc. in Florida; AmeriHealth Caritas North Carolina, Inc. in North Carolina; and First Choice Next by Select Health of South Carolina, Inc. in South Carolina.